IntelGenx Announces Closing of Notes Offering
05 8월 2021 - 11:30PM
IntelGenx Technologies Corp. (TSXV: IGX) (OTCQB: IGXT) (the
“
Company” or “
IntelGenx”)
announces the closing of an offering by way of private placement
(the “
Offering”) to certain investors in the
United States of 8% convertible notes due July 31, 2025 (the
“
Notes”) for aggregate gross proceeds of
approximately U.S.$2.1 million. The Notes will bear interest at a
rate of 8% per annum, payable quarterly, and will be convertible
into shares of common stock of the Company (the
“
Shares”) beginning 6 months after their issuance
at a price of U.S.$0.40 per Share.
Cantone Research, Inc.
(“Cantone”) acted as placement agent in respect of
the Offering.
The Company intends to use the proceeds of the
Offering to finance its Montelukast study.
In connection with the Offering, the Company
paid Cantone a cash commission of approximately U.S.$199,525 in the
aggregate and issued non-transferable warrants to the agent
(the “Agent’s Warrants”), entitling Cantone
to purchase 613,000 Shares at a price of U.S.$0.40 per Share until
August 4, 2023. The TSX Venture Exchange (the
“TSXV”) has conditionally approved the listing of
the Shares issuable upon conversion of the Notes, as well as the
Shares issuable upon exercise of the Agent’s Warrants. Listing on
the TSXV will be subject to the Company fulfilling all of the
listing requirements of the TSXV.
This press release does not constitute an offer
to sell, or a solicitation of an offer to buy, securities in any
jurisdiction where not permitted by law. Any securities described
in this announcement have not been registered under the United
States Securities Act of 1933, as amended (the “U.S.
Securities Act”), or any state securities laws, and may
not be offered or sold in the United States, or to, or for the
account or benefit of a “U.S. person” as defined in Regulation S
under the U.S. Securities Act, except in transactions exempt from,
or not subject to, registration under the U.S. Securities Act and
applicable state securities laws.
About IntelGenx
IntelGenx is a leading drug delivery company
focused on the development and manufacturing of pharmaceutical
films.
IntelGenx’s superior film technologies,
including VersaFilm®, DisinteQ™, VetaFilm™ and transdermal
VevaDerm™, allow for next generation pharmaceutical products that
address unmet medical needs. IntelGenx’s innovative product
pipeline offers significant benefits to patients and physicians for
many therapeutic conditions.
IntelGenx's highly skilled team provides
comprehensive pharmaceuticals services to pharmaceutical partners,
including R&D, analytical method development, clinical
monitoring, IP and regulatory services. IntelGenx's
state-of-the-art manufacturing facility offers full service by
providing lab-scale to pilot- and commercial-scale production. For
more information, visit www.intelgenx.com.
Forward-Looking Information and
Statements
This document may contain forward-looking
information or forward-looking statements within the meaning of
applicable United States and Canadian securities laws
(collectively, “forward-looking statements”). These statements are
statements that are not purely historical and include, but are not
limited to, statements about the obtaining the TSXV’s final
approval and the use of proceeds from the Offering. All
forward-looking statements are expressly qualified in their
entirety by this cautionary statement. Because these
forward-looking statements are subject to a number of risks and
uncertainties, IntelGenx's actual results could differ materially
from those expressed or implied by these forward-looking
statements.
Factors that could cause or contribute to such
differences include, but are not limited to, the factors discussed
under the heading “Risk Factors” in IntelGenx’s annual report on
Form 10-K, filed with the United States Securities and Exchange
Commission and available at www.sec.gov, and also filed with
Canadian securities regulatory authorities and www.sedar.com.
IntelGenx assumes no obligation to update any such forward-looking
statements IntelGenx assumes no obligation to update any such
forward-looking statements.
Although the Company believes that the
expectations and assumptions on which forward-looking statements
are based are reasonable, readers of this press release are
cautioned not to rely unduly on such forward-looking statements
since no assurance can be given that they will prove to be correct.
The Company does not undertake any obligation to update or revise
any forward-looking statements, whether as a result of events or
circumstances occurring after the date of this press release,
unless so required by legislation.
Each of the TSX Venture Exchange and OTCQB has
neither approved nor disapproved the contents of this press
release. Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
No securities regulatory authority has either
approved or disapproved of the contents of this press release. This
press release does not constitute an offer to sell or a
solicitation of an offer to buy any securities of the Company in
any jurisdiction in which such offer or solicitation of sale would
be unlawful.
For more information, please
contact:
Stephen KilmerInvestor Relations(514) 331-7440
ext 232stephen@intelgenx.com
Or
Andre Godin, CPA, CAPresident and CFOIntelGenx
Corp.(514) 331-7440 ext 203andre@intelgenx.com
Intelgenx Technologies (TSXV:IGX)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Intelgenx Technologies (TSXV:IGX)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024